Effects of a memory enhancing peptide on cognitive abilities of brain-lesioned mice: Additivity with huperzine A and relative potency to tacrine

Journal of Peptide Science

Volumn 12, Issue 1, 2006, Pages 72-78

  Xu, Zhiwen ^a   Zheng, Hui ^a   Law, Sek Lun ^a   So, Donna Dong ^a   Han, Yifan ^a   Xue, Hong ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Brain lesioned mice; Huperzine A; Memory enhancing peptide; Passive avoidance response; Scopolamine; Tacrine; Y water maze

Indexed keywords

ARGIPRESSIN DERIVATIVE; HUPERZINE A; SCOPOLAMINE; TACRINE;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG POTENTIATION; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOMES RESEARCH; PASSIVE AVOIDANCE; PRIORITY JOURNAL;

ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN DISEASES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; MEMORY; MICE; PEPTIDE FRAGMENTS; SCOPOLAMINE; SESQUITERPENES; TACRINE;

ANIMALIA;

EID: 29844442018     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.682     Document Type: Article

References (32)

1. Cummings J, Khachaturian Z. Definitions and diagnostic criteria. In Clinical Diagnosis and Management of Alzheimer's Disease, Gauthier S (ed.). Martin Dunitz: London, 1999; 3-15.
2. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-1190.
3. Giacobini E. Nicotinic cholinergic receptors in human brain: effects of aging and Alzheimer. Adv. Exp. Med. Biol. 1991; 296: 303-315.
4. Giacobini E. The second generation of cholinesterase inhibitors: pharmacological aspects. In Cholinergic Basis for Alzheimer's Therapy, Becher R, Giacobini E (eds). Birkhauser: Boston: 1991; 247-262.
5. Pomponi M, Giacobini E, Brufani M. Present state and future development of the therapy of Alzheimer disease. Aging (Milano) 1990; 2: 125-153.
6. Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav. Neural. Biol. 1986; 45: 196-211.
7. Bejar C, Wang RH, Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur. J. Pharmacol. 1999; 383: 231-240.
8. Kim YK, Koo BS, Gong DJ, Lee YC, Ko JH, Kim CH. Comparative effect of Prunus persica L. Batsch-water extract and tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride) on concentration of extracellular acetylcholine in the rat hippocampus. J. Ethnopharmacol. 2003; 87: 149-154.
9. Nikolov R. Alzheimer's disease therapy - An update. Drug News Perspect. 1998; 11: 248-255.
10. Ames DJ, Bhathal PS, Davies BM, Fraser JR. Hepatotoxicity of tetrahydroaminoacridine. Lancet 1988; 1: 887.
11. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
12. Stephens LR, Logan SD. Arginine-vasopressin stimulates inositol phospholipid metabolism in rat hippocampus. J. Neurochem. 1986; 46: 649-651.
13. Ishunina TA, Swaab DF. Neurohypophyseal peptides in aging and Alzheimer's disease. Ageing Res. Rev. 2002; 1: 537-558.
14. De Wied D, Gaffori O, Van Ree JM, De Jong W. Vasopressin antagonists block peripheral as well as central vasopressin receptors. Pharmacol. Biochem. Behav. 1984; 21: 393-400.
15. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav. 2003; 75: 675-686.
16. Xiong ZQ, Tang XC. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol. Biochem. Behav. 1995; 51: 415-419.
17. Wang YE, Yue DX, Tang XC. [Anti-cholinesterase activity of huperzine Al. Zhongguo Yao Li Xue Bao 1986; 7: 110-113.
18. Huperzine A. Drugs R. D. 2004; 5: 44-45.
19. Jiang H, Luo X, Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. Curr. Med. Chem. 2003; 10: 2231-2252.
20. Burbach JP, Kovacs GL, de Wied D, van Nispen JW, Greven HM. A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. Science 1983; 221: 1310-1312.
21. Lin C, Liu RY, Du YC. Cysteinyl methyl ester of AVP(4-8), a potent agonist on the maintenance of passive avoidance in rats. Peptides 1990; 11: 633-639.
22. Liu RY, Lin C, Du YC. [Facilitation of arginine-vasopressin analogs on learning and memory in rats]. Zhongguo Yao Li Xue Bao 1990; 11: 97-100.
23. Maegawa H, Katsube N, Okegawa T, Aishita H, Kawasaki A. Arginine-vasopressin fragment 4-9 stimulates the acetylcholine release in hippocampus of freely-moving rats. Life Sci. 1992; 51: 285-293.
24. Zhou AW, Guo J, Wang HY, Gu BX, Du YC. Enhancement of NGF gene expression in rat brain by the memory-enhancing peptide AVP(4-8). Peptides 1995; 16: 581-586.
25. Fujiwara M, Ohgami Y, Inada K, Iwasaki K. Effect of active fragments of arginine-vasopressin on the disturbance of spatial cognition in rats. Behav. Brain Res. 1997; 83: 91-96.
26. Zhou AW, Guo J, Du YC. NLPR, an agonist of AVP4-8, increases NGF gene expression in memory-impaired rat brain. Biomed. Pept. Proteins Nucleic Acids 1994; 1: 57-58.
27. Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J. Mol. Neurosci. 2003; 20: 349-356.
28. Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann. N. Y. Acad. Sci. 1996; 777: 189-196.
29. Knipper M, Breer H. Muscarinic receptors modulating acetylcholine release from insect synaptosomes. Comp. Biochem. Physiol. C 1989; 93: 287-292.
30. Loffelholz K. Brain choline has a typical precursor profile. J. Physiol. Paris 1998; 92: 235-239.
31. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol. Biochem. Behav. 1998; 60: 377-386.
32. Denke MA. Coadministration of multidrug therapy to achieve lipid goals. J. Am. Osteopath. Assoc. 2004; 104: S17-S22.